PTO/SB/08a (05-07)

Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number Filing Date		10568572 2006-08-14	
	First Named Inventor Art Unit	Lope	z de Diego et al. 1614	
	Examiner Name Attorney Docket Numb	N/A 453-US-PCT		

			•••••		U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C)ate	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines where ant Passages or Releves Appear	
/E.B./	1	6444854	B1	2002-0	9-03	Dapremont et al.				
/E.B./	2	6506940	B1	2003-0	1-14	Jadav et al.				
If you wish to add additional U.S. Patent citation information please click the Add button.										
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee o Date of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	r citatio	n information p	olease click the Ad	d butto	n.	
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
/E.B./	1	95/15299	wo		А1	1995-06-08	Pfizer Inc.			
/E.B./	2	05/16901	wo		A1	2005-02-24	H. Lundbeck A/S			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568572	
Filing Date		2006-08-14	
First Named Inventor	Lope	z de Diego et al.	
Art Unit		1614	
Examiner Name	N/A	· · · · · · · · · · · · · · · · · · ·	
Attorney Docket Number		453-US-PCT	

n 10 a	dd additional Foreign Patent Document citation information please click the Add button	
	NON-PATENT LITERATURE DOCUMENTS	***********
Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	ŢS
1	BALSARA, J. J. et al. Effect of Drugs Influencing Central Serotonergic Mechanisms on Haloperidol-Induced Catalepsy. Psychopharmacol. 1979. 62:67-69.	
2	CARLSSON, A. Antipsychotic Drugs, Neurotransmitters, and Schizophrenia. Am. J. Psych. 1978. 135(2):164-173.	
3	CARLSSON, L. et al. QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiamhythmic Agents in the Rabbit: Etiology and Interventions. J. Cardiovasc. Pharmacol. 1990. 16:276-285.	
√ 4	CHAURET, N. et al. The Use of 3-[2-(N,N-Diethyl-N-Methylammonium)Ethyl]-7-Methoxy-4-Methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes. Drug Metab. Dispos. 2001. 29(9):1196-1200.	
5	COX. G.B. (ed.) Preparative Enantioselective Chromatography. Oxford. UK: Blackwell Publishing Ltd. 2005.	
⁷ 6	HYTTEL, J. et al. Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin. J. Neurochem. 1985. 44:1615-1622.	
000000000000	WILLNER, P. Dopamine and Depression: A Review of Recent Evidence, II. Theoretical Approaches, Brain Res, Rev. 1983, 6(3):225-236.	2000000000
000000000000000000000000000000000000000	WILLNER, P. Dopamine and Depression: A Review of Recent Evidence. III. The Effects of Antidepressant Treatments. Brain Res. Rev. 1983. 6(3):237-246.	••••••••••
	Cite No 1 2	NON-PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. BALSARA, J. J., et al. Effect of Drugs Influencing Central Serotonergic Mechanisms on Haloperidol-Induced Catalepsy. Psychopharmacol. 1979. 62:67-69. CARLSSON, A. Antipsychotic Drugs. Neurotransmitters, and Schizophrenia. Am. J. Psych. 1978. 135(2):164-173. CARLSSON, L. et al. QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit. Etiology and Interventions. J. Cardiovasc. Pharmacol. 1990. 16:276-285. CHAURET, N. et al. The Use of 3-{2-{N.N-Diethyl-N-Methylammonium}Ethyll-7-Methoxy-4-Methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes. Drug Metab. Dispos. 2001. 29(9):1196-1200. COX. G.B. (ed.) Preparative Enantioselective Chromatography. Oxford. UK: Blackwell Publishing Ltd. 2005. HYTTEL, J. et al. Neurochemical Profile of Lu. 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin. J. Neurochem. 1985. 44:1615-1622. WILLNER, P. Dopamine and Depression. A Review of Recent Evidence. III. Theoretical Approaches. Brain Res. Rev. 1983. 6(3):225-236.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568572	
Filing Date		2006-08-14	
First Named Inventor Lope:		z de Diego et al.	
Art Unit		1614	
Examiner Name	N/A	N/A	
Attomey Docket Number		453-US-PCT	

	EXAMINER	RSIGNATURE
Examiner Signature	/Emily Bernhardt/	Date Considered 01/17/2009
· ·	•	tion is in conformance with MPEP 609. Draw line through a rof this form with next communication to applicant.
Standard ST.3). 3 For Japanese	patent documents, the indication of the year or priate symbols as indicated on the document u	P 901.04. ² Enter office that issued the document, by the two-letter code (WIPO if the reign of the Emperor must precede the serial number of the patent document, inder WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if